Catalyst Pharma sees net price of drug, once free, topping $300,000

Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

This article discusses the mechanisms involved in the pathogenesis of CS and the pros and the cons of the various antihypertensive agents that are presently available to treat these patients.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
We describe the clinical features and course of a patient harboring the rare p.V32A (c.155T>C) variant that was previously described in only two patients and whose pathogenicity was unclear.
Source: Neurological Sciences - Category: Neurology Source Type: research
supporting studies that advance rare disease product development
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
Acromegaly is a rare disease with vocal changes being a common clinical finding. The authors present a very rare case of an opera singer with undetected acromegaly for years, whose tessiture progressively changed from tenor, to baritone, to bass. We analyze the evolution of vocal parameters over the years and the outcome after surgical treatment.
Source: Journal of Voice - Category: ENT & OMF Authors: Source Type: research
ConclusionsWe found a high willingness-to-pay for innovative drugs in oncology and hematology. The wide range of responses observed, however, indirectly implies a lack of consensus on the use of explicit ICER thresholds in Bulgaria.
Source: Value in Health Regional Issues - Category: International Medicine & Public Health Source Type: research
Conclusion: Automated detection of macular diseases from OCT images might be feasible using the CNN model. Image augmentation might be effective to compensate for a small image number for training. PMID: 31093370 [PubMed]
Source: Journal of Ophthalmology - Category: Opthalmology Tags: J Ophthalmol Source Type: research
Authors: Liebowitz J, Hellmann DB, Schnappauf O Abstract Three sisters of Northern European descent provided an opportunity to examine the longterm course and possible familial aspects of a rare disease, polyarteritis nodosa (PAN). Approval and consent was obtained from each patient. PMID: 31092714 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
Conditions:   Rare Diseases;   Genetic Predisposition Intervention:   Genetic: WGS-Diagnostic Sponsor:   University Hospital Tuebingen Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Esophageal adenocarcinoma (EAC) is one of the cancers with the most rapidly rising incidence in the West. In the East, EAC is still a relatively rare disease, despite a slight increase that may be explained by a rise in obesity resulting from Westernized eating habits and by a decline in Helicobacter pylori infection.1 This is also reflected by the study by Abe and colleagues,2 including 372 patients, in 13 participating centers, over an inclusion period of 11 years, which comes down to about 2 to 3 patients with EAC treated with endoscopic resection per center per year.
Source: Gastrointestinal Endoscopy - Category: Gastroenterology Authors: Tags: Original article Source Type: research
ConclusionHealth information seeking and sharing are important aspects of rare disease patients ’ everyday life. Challenges they face could be overcome in cooperation with patient support groups, health care professionals and health information professionals.
Source: Health Information and Libraries Journal - Category: Databases & Libraries Authors: Tags: Original Article Source Type: research
More News: Health | Insurers | Pharmaceuticals | Rare Diseases